Panbela Therapeutics Company Description
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer.
The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications.
Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020.
Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Jennifer Simpson |
Contact Details
Address: 712 Vista Boulevard Waconia, Minnesota Minnesota United States | |
| Phone | 952 479 1196 |
Stock Details
| Ticker Symbol | PBLA |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US69833W1071 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. | Chief Executive Officer, President and Director |
| Susan Horvath | Vice President of Finance, Chief Financial Officer, Secretary and Treasurer |
| Tammy Groene | Vice President of Operations |